Innate Pharma EBIT Margin

What does Innate Pharma do? Innate Pharma S.A. is a biotechnology company based in Marseille, France, operating within the Health Care sector. The company focuses on developing immunotherapies for cancer patients, with a portfolio of clinical-stage products. Innate Pharma has 125 employees and went public via an IPO on October 17, 2019. Its website is https://www.innate-pharma.com. The company is listed under the ticker IPHA with ISIN US45781K2042. Innate Pharma is engaged in developing various therapeutic candidates, including Lacutamab (IPH4102), an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma. Other pipeline products include IPH4502, a topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; IPH5201, a CD39-targeting antibody in Phase II; IPH5301, an anti-CD73 antibody targeting the adenosine pathway; IPH6401, a BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager targeting CD123; and IPH62, a B7-H3-targeting NK cell engager. The company also has IPH6501, a tetra-specific NK cell engager targeting CD20 and interleukin-2 receptor. Innate Pharma collaborates with major pharmaceutical companies including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. The company's operations are primarily focused on advancing these immunotherapies through clinical development and strategic partnerships. Innate Pharma is one of the most popular companies on Eulerpool.